Responses of splenomegaly, constitutional symptoms, and pruritus to RAD001 therapy. The proportion of patients who presented variable reduction of splenomegaly at 1 and 4 months of therapy, expressed as percent change from the baseline, is shown in panel A. The decrease of spleen enlargement was already maximal at 1 month, and it was maintained up to the end of treatment. Panel B and C represent the proportion of patients who presented constitutional symptoms (B) or pruritus (C) at baseline and their response to therapy at each month. Only patients who reported complete disappearance of night sweats, fever (B), or pruritus (C) were considered as responders.